Parexel debuts new patient-centric solutions for drug development

Patients in a hospital waiting room
Parexel debuts new patient-centric solutions using its Perceptive Cloud platform and leveraging its relationship with Microsoft. (Getty/SuwanPhoto)

Parexel has rolled out several new patient-centric solutions using its Perceptive Cloud platform and leveraging the CRO’s relationship with Microsoft to aid in drug development.

The new rollout incorporates mobile and wearable tech to speed and enhance access to data for better patient interactions during clinical research, the company said.

The first solution leverages Microsoft’s Azure App Services to harvest and send health alerts from mobile devices that will gives clinical staff and investigators automatic data updates in order to monitor potential threats to patient safety and decrease the risk of patient mortality and morbidity.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Additionally, the company announced that its Patient Sensor Solution will now include more connected medical devices. Parexel’s Sensor Solution uses AI for predictive patient compliance monitoring, which has been expanded to manage increased data transfer.

“Technology has made it possible to access more meaningful data than ever before, while improving the patient experience,” Douglas Barta, Parexel’s chief information officer, said in a statement. “The challenge is in collecting that data in a way that is efficient for the patient, site, and investigator.”

Parexel has been busy recently beefing up its offerings and partnerships.

In late September, it announced a partnership with healthcare tech company Datavant to improve the design and operations of clinical studies and generate more real-world evidence. That news came close on the heels of the company opening its Patient Innovation Center focused on boosting efficiency and success in biopharma development areas including clinical trial design, recruitment, execution and market access.

Suggested Articles

WIRB-Copernicus Group has added two new executives to its roster as it expands its Global Research Network of investigative sites.

Incoming FDA Commissioner Ned Sharpless used his first official talk to ensure we all know he’s not looking to tear up Scott Gottlieb’s legacy.

Charles River Labs and the CHDI Foundation have signed a five-year extension for their Huntington’s disease work.